Emcure Pharmaceuticals Ltd - Asset Resilience Ratio

Latest as of September 2025: 1.38%

Emcure Pharmaceuticals Ltd (EMCURE) has an Asset Resilience Ratio of 1.38% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

Rs1.29 Billion
≈ $13.98 Million USD Cash + Short-term Investments

Total Assets

Rs93.93 Billion
≈ $1.02 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2022–2025)

This chart shows how Emcure Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. See financial agility of Emcure Pharmaceuticals Ltd to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down Emcure Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see EMCURE market cap.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Rs0.00 0%
Short-term Investments Rs1.29 Billion 1.38%
Total Liquid Assets Rs1.29 Billion 1.38%

Asset Resilience Insights

  • Limited Liquidity: Emcure Pharmaceuticals Ltd maintains only 1.38% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Emcure Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio

Compare Emcure Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
Drug Manufacturers - Specialty & Generic 0.16%
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Ajanta Pharma Limited
NSE:AJANTPHARM
Drug Manufacturers - Specialty & Generic 14.99%
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
Drug Manufacturers - Specialty & Generic 48.48%
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
Drug Manufacturers - Specialty & Generic 5.92%
Tianjin Ringpu Bio Tech
SHE:300119
Drug Manufacturers - Specialty & Generic 14.27%
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702
Drug Manufacturers - Specialty & Generic 0.00%
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
Drug Manufacturers - Specialty & Generic 0.29%

Annual Asset Resilience Ratio for Emcure Pharmaceuticals Ltd (2022–2025)

The table below shows the annual Asset Resilience Ratio data for Emcure Pharmaceuticals Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-03-31 0.92% Rs760.43 Million
≈ $8.22 Million
Rs82.33 Billion
≈ $890.34 Million
-2.78pp
2024-03-31 3.70% Rs2.89 Billion
≈ $31.28 Million
Rs78.06 Billion
≈ $844.21 Million
+0.64pp
2023-03-31 3.06% Rs2.04 Billion
≈ $22.11 Million
Rs66.73 Billion
≈ $721.61 Million
+0.66pp
2022-03-31 2.40% Rs1.46 Billion
≈ $15.74 Million
Rs60.63 Billion
≈ $655.74 Million
--
pp = percentage points

About Emcure Pharmaceuticals Ltd

NSE:EMCURE India Drug Manufacturers - Specialty & Generic
Market Cap
$4.06 Billion
Rs375.08 Billion INR
Market Cap Rank
#4085 Global
#184 in India
Share Price
Rs1978.40
Change (1 day)
+2.15%
52-Week Range
Rs1271.80 - Rs1978.40
All Time High
Rs1978.40
About

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure X… Read more